The Orphan Drug Act of 1983: A case study of issue framing and the failure to effect policy change from 1990--1994
by Redington, Lynn, Dr.P.H., THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, 2009, 190 pages; 3352655

Abstract:

Both low- and high-commercial-potential (LCP and HCP) orphan drugs are eligible for benefits provided by the Orphan Drug Act of 1983 (ODA). During 1990-1994, legislators attempted to amend the law to better target benefits to LCP drugs and “restore the spirit of the law” to promote the development of LCP drugs for rare diseases that might otherwise be abandoned, or “orphaned.” These amendment attempts were not successful.

This dissertation research examines: (1) how ODA stakeholders attempted to shape the debate about HCP orphan drugs in the 1990s, and, (2) potential factors that may have impeded or promoted ODA reform in the 1990s.

ODA reforms were debated in four Congressional hearings from 1990-1994. Hearing transcripts were obtained and thirty-eight statements were coded. The qualitative research method of memoing was used to construct four frames from the Congressional text: (1) ODA Reform as Economics and Access, (2) ODA Reform as Patient Relief, (3) ODA Reform as Rules of Participation, and (4) ODA Reform as Congressional Action.

Potential reform factors were proposed a priori and subsequently evaluated based on a review of over 100 documents and ten informant interviews.

The research offers a microcosmic window into how policy stakeholders define problems, propose solutions, and advance their interests in debates over social conditions and public policies. In the 1990s, legislators asked: does market exclusivity for HCP orphan drugs provide an unnecessary monopoly that leads to excessively high orphan drug prices, windfall profits, and other problems? The research illustrates how disputants chose to define, or avoid defining, terms such as “unnecessary monopolies,” “excessively high drug prices,” “windfall profits,” and “problems” that result from these conditions.

The research demonstrates how policy development and framing theory can structure inquiry into attempted policy reform, aid in developing a priori hypotheses, and, shape analyses and recommendations. The dissertation includes a guide for analyzing policy development and a guide for constructing and deconstructing issue frames. These are applied to the historical case of attempted ODA reforms, but may be useful for other cases.

 
AdviserThomas C. Ricketts
SchoolTHE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
SourceDAI/B 70-04, p. , May 2009
Source TypeDissertation
SubjectsPharmaceutical sciences; Public health; Health care management
Publication Number3352655
Adobe PDF Access the complete dissertation:
 

» Find an electronic copy at your library.
  Use the link below to access a full citation record of this graduate work:
  http://gateway.proquest.com/openurl%3furl_ver=Z39.88-2004%26res_dat=xri:pqdiss%26rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation%26rft_dat=xri:pqdiss:3352655
  If your library subscribes to the ProQuest Dissertations & Theses (PQDT) database, you may be entitled to a free electronic version of this graduate work. If not, you will have the option to purchase one, and access a 24 page preview for free (if available).

About ProQuest Dissertations & Theses
With over 2.3 million records, the ProQuest Dissertations & Theses (PQDT) database is the most comprehensive collection of dissertations and theses in the world. It is the database of record for graduate research.

The database includes citations of graduate works ranging from the first U.S. dissertation, accepted in 1861, to those accepted as recently as last semester. Of the 2.3 million graduate works included in the database, ProQuest offers more than 1.9 million in full text formats. Of those, over 860,000 are available in PDF format. More than 60,000 dissertations and theses are added to the database each year.

If you have questions, please feel free to visit the ProQuest Web site - http://www.proquest.com - or call ProQuest Hotline Customer Support at 1-800-521-3042.